NEW YORK – The COVID-19 pandemic has thus far presented many life science research tool providers and fledgling diagnostic firms with an immediate opportunity to generate meaningful revenues from diagnostic testing in 2020.
For some firms, this opportunity may be short-lived. For others, it will perhaps serve as a launching pad for sustainable, long-term growth driven by diagnostic testing.
Fluidigm President and CEO Chris Linthwaite this week made it clear that he sees his company, long a pure-play omics research firm, in the latter category.